Lead Product(s) : Bivalirudin
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market
Details : Angiomax-Generic (bivalirudin) is a direct thrombin inhibitor launched in the US, indicated for heparin-induced thrombocytopenia and thrombosis syndrome.
Product Name : Angiomax-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
January 29, 2024
Lead Product(s) : Bivalirudin
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bivalirudin
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo Launches Bivalirudin Injection in Ready-to-Use Vials
Details : Bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S.
Product Name : Angiomax RTU
Product Type : Peptide
Upfront Cash : Inapplicable
July 18, 2023
Lead Product(s) : Bivalirudin
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bivalirudin
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : MAIA Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to distribute Angiomax RTU (bivalirudin) injection, a direct thrombin inhibitor used to prevent blood clots in people with severe chest pain or other conditions who are undergoing a procedure called angioplasty, in the U.S.
Product Name : Angiomax RTU
Product Type : Peptide
Upfront Cash : Undisclosed
May 24, 2023
Lead Product(s) : Bivalirudin
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : MAIA Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
